688606.SH
Hangzhou Alltest Biotech Co., Ltd.
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 47.64
−0.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 892.2M | 905.3M | 866.6M | 754.7M | 3.4B |
| Cost of Revenue | 443.6M | 444.1M | 383.7M | 386.5M | 1.4B |
| Gross Profit | 448.7M | 461.3M | 482.8M | 368.2M | 2.0B |
| Operating Expenses | |||||
| R&D Expense | 116.9M | 109.3M | 95.8M | 121.2M | 207.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 84.4M | 79.7M | 64.8M | 66.6M | 78.1M |
| Selling & Marketing Expense | 82.1M | 79.3M | 55.4M | 69.3M | 150.3M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 302.9M | 267.5M | 188.2M | 205.5M | 392.6M |
| Cost and Expenses | 746.5M | 711.6M | 571.9M | 592.1M | 1.8B |
| Operating Income (EBIT) | 208.9M | 251.8M | 345.5M | 211.6M | 1.4B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 208.4M | 251.2M | 347.7M | 197.4M | 1.4B |
| Income Tax Expense | 30.4M | 31.1M | 44.8M | 17.2M | 196.0M |
| Bottom Line | |||||
| Net Income | 178.4M | 220.2M | 302.5M | 180.6M | 1.2B |
| Earnings from Cont. Ops | 178.0M | 220.1M | 302.9M | 180.3M | 1.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 178.4M | 220.2M | 302.5M | 180.6M | 1.2B |
| Per Share | |||||
| Basic EPS | CN¥2.25 | CN¥2.78 | CN¥3.82 | CN¥2.28 | CN¥14.95 |
| Diluted EPS | CN¥2.25 | CN¥2.78 | CN¥3.82 | CN¥2.28 | CN¥14.95 |
| Revenue Per Share | CN¥11.04 | CN¥11.43 | CN¥10.94 | CN¥9.53 | CN¥42.75 |
| Shares | |||||
| Basic Shares Outstanding | 80.8M | 79.2M | 79.2M | 79.2M | 79.3M |
| Diluted Shares Outstanding | 80.8M | 79.2M | 79.2M | 79.2M | 79.3M |
| Profitability Metrics | |||||
| EBITDA | — | 297.2M | 381.6M | 242.9M | 1.4B |
| D&A | — | 45.4M | 36.1M | 31.3M | 30.1M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026